Lu-PSMA + Enzalutamide
Phase 2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castration-Resistant Prostate Cancer
Conditions
Metastatic Castration-Resistant Prostate Cancer
Trial Timeline
Aug 17, 2020 → Jan 1, 2025
NCT ID
NCT04419402About Lu-PSMA + Enzalutamide
Lu-PSMA + Enzalutamide is a phase 2 stage product being developed by Astellas Pharma for Metastatic Castration-Resistant Prostate Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT04419402. Target conditions include Metastatic Castration-Resistant Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castration-Resistant Prostate Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04419402 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Metastatic Castration-Resistant Prostate Cancer